PharmaCyte Biotech PMCB
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
PharmaCyte Biotech (PMCB) Business Model and Operations Summary
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Key Insights
PharmaCyte Biotech (PMCB) Core Market Data and Business Metrics
Latest Closing Price
$1.103Market Cap
$7.21 MillionAverage Daily Volume
12,112 Shares52-Week Range
$1-$2.4229Total Outstanding Shares
6.86 Million SharesCEO
Joshua N. SilvermanTotal Employees
2IPO Date
September 11, 2003SIC Description
Biological Products, (no Disgnostic Substances)Headquarters
23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA, 92653
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Short Interest
This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.
Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|